APA (7th ed.) Citation

W, Y., F, M., DL, B., P, K., D, V., F, M., . . . AA, S. (2022). Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects. British journal of clinical pharmacology, 88(2), 600. https://doi.org/10.1111/bcp.14975

Chicago Style (17th ed.) Citation

W, Yin, Mamashli F, Buhl DL, Khudyakov P, Volfson D, Martenyi F, Gevorkyan H, Rosen L, and Simen AA. "Safety, Pharmacokinetics and Quantitative EEG Modulation of TAK-071, a Novel Muscarinic M1 Receptor Positive Allosteric Modulator, in Healthy Subjects." British Journal of Clinical Pharmacology 88, no. 2 (2022): 600. https://doi.org/10.1111/bcp.14975.

MLA (9th ed.) Citation

W, Yin, et al. "Safety, Pharmacokinetics and Quantitative EEG Modulation of TAK-071, a Novel Muscarinic M1 Receptor Positive Allosteric Modulator, in Healthy Subjects." British Journal of Clinical Pharmacology, vol. 88, no. 2, 2022, p. 600, https://doi.org/10.1111/bcp.14975.